文献速递肿瘤 PET/CT甲状腺核医学

18F-氟雌二醇PET显像检测乳腺癌雌激素受体α激活突变

18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer.
PubMed 文献 · J Nucl Med · 2019-03-08

本研究在ER阴性乳腺癌细胞中稳定表达野生型ER或Y537S/Y537C突变ER,比较18F-FES结合与体内肿瘤摄取。结果显示Y537S和Y537C突变增加ER转录活性,但18F-FES的Kd、IC50及肿瘤摄取与野生型ER无显著差异。结论认为18F-FES PET对携带或不携带这些激活型ESR1突变的患者诊断价值可能相同。

要点

  • Y537S和Y537C突变导致ER在无雌激素时转录活性增加。
  • Y537S-ER和Y537C-ER的18F-FES亲和力与野生型ER无显著差异。
  • 表达Y537S或Y537C的肿瘤异种移植瘤18F-FES摄取与野生型相似。

核心结论

  • Y537S-ER或Y537C-ER突变未显著影响肿瘤对18F-FES的摄取,18F-FES PET诊断价值可能不受这些激活型ESR1突变影响。

研究设计与样本

  • 研究使用ER阴性MDA-MB-231乳腺癌细胞生成稳定表达野生型ER、Y537S或Y537C突变ER的细胞系。
  • 通过Western blot和免疫荧光确认受体表达与定位,用雌激素反应元件-荧光素酶报告基因和qPCR分析ER转录功能。
  • 进行饱和结合与竞争实验测定Kd和IC50,并在雌性无胸腺裸鼠肿瘤异种移植瘤中用small-animal PET/CT和组织生物分布测量18F-FES摄取。
  • 18F-FES剂量为5.55 MBq(150 μCi),另用10倍低剂量0.555 MBq(15 μCi)进行组织生物分布。
  • 统计分析采用ANOVA。

主要发现

  • Y537S和Y537C突变在无雌激素时ER转录活性较WT-ER增加:Y537S为11.48 ± 2.42倍(P = 0.0002),Y537C为5.89 ± 0.94倍(P = 0.04)。
  • 无雌激素时Y537S-ER和Y537C-ER细胞中PGR和TFF1两个靶基因组成性激活。
  • 18F-FES的Kd值:Y537S-ER为0.98 ± 0.54 nM(P = 0.27),Y537C-ER为0.24 ± 0.03 nM(P = 0.95),WT-ER为0.07 ± 0.03 nM。
  • IC50值:Y537S-ER为0.22 ± 0.09 nM(P = 0.97),Y537C-ER为0.18 ± 0.09 nM(P = 0.99),WT-ER为0.19 ± 0.11 nM。
  • 肿瘤异种移植瘤18F-FES摄取(%ID/g):Y537S-ER为1.45 ± 0.06(P = 0.77),Y537C-ER为2.09 ± 0.20(P = 0.21),WT-ER为1.68 ± 0.12;10倍低剂量组织生物分布结果类似。

临床怎么用

  • 对于携带Y537S或Y537C激活型ESR1突变的乳腺癌患者,18F-FES PET显像的诊断价值可能与野生型ER患者相同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to determine the effect of estrogen receptor-α gene (ESR1) mutations at the tyrosine (Y) 537 amino acid residue within the ligand binding domain on 18F-fluoroestradiol (18F-FES) binding and in vivo tumor uptake compared with wild-type (WT)-estrogen receptor α (ER). Methods: ER-negative MDA-MB-231 breast cancer cells were used to generate stable cell lines that express WT-ER, Y537S, or Y537C mutant ER. Receptor expression and localization were confirmed by Western blot and immunofluorescence, respectively. ER transcriptional function was measured using an estrogen response element-luciferase reporter gene assay and quantitative polymerase chain reaction analysis of ER-regulated endogenous target genes. Saturation binding and competition assays were performed to determine equilibrium dissociation constant (Kd) and half maximal inhibitory concentration (IC50) values. 18F-FES uptake was measured in tumor xenografts grown in female athymic nude mice by small-animal PET/CT imaging and tissue biodistribution using 5.55 MBq (150 μCi) of 18F-FES. A 10-fold-lower injected dose of 0.555 MBq (15 μCi) of 18F-FES was also used for tissue biodistribution. Statistical significance was determined using ANOVA. Results: Y537S and Y537C mutations resulted in increased ER transcriptional activity in the absence of estrogen compared with WT-ER (11.48 ± 2.42 fold; P = 0.0002, and 5.89 ± 0.94 fold; P = 0.04, respectively). Constitutive ER activation of two target genes (PGR and TFF1) in the absence of estrogen was also observed in Y537S- and Y537C-ER cells compared with WT-ER. Kd values for 18F-FES were 0.98 ± 0.54 nM for Y537S-ER (P = 0.27) and 0.24 ± 0.03 nM for Y537C-ER (P = 0.95) compared with 0.07 ± 0.03 nM for WT-ER. IC50 values were 0.22 ± 0.09 nM for Y537S-ER (P = 0.97), 0.18 ± 0.09 nM for Y537C-ER (P = 0.99), and 0.19 ± 0.11 nM for WT-ER. Tumor xenografts expressing Y537S-ER (mean percentage injected dose per gram, 1.45 ± 0.06; P = 0.77) and Y537C-ER (2.09 ± 0.20; P = 0.21) had similar 18F-FES uptake compared with WT-ER (1.68 ± 0.12). Comparable 18F-FES uptake between Y537S-, Y537C-, and WT-ER xenografts was also observed using a 10-fold-lower injected dose with the tissue biodistribution assay. Conclusion: Since tumoral uptake of 18F-FES is not significantly impacted by Y537S-ER or Y537C-ER mutations, the potential diagnostic utility of 18F-FES PET imaging is expected to be equally valid for patients with or without these activating ESR1 mutations.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kumar M, Salem K, Michel C, et al. 18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer. J Nucl Med. 2019. PMID: 30850489. doi:10.2967/jnumed.118.224667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。